The National Cancer Institute approved the following clinical research studies last month.
A personalized mRNA cancer vaccine sponsored by Moderna and Merck has the potential to change the standard of care for melanoma patients—and reshape the landscape of cancer vaccines—if the company’s latest data on the vaccine are validated in a phase III clinical trial.
The NCI Board of Scientific Advisors unanimously approved six new concepts and two reissue concepts at a joint meeting of the BSA and the National Cancer Advisory Board.
In 1991, NCI recorded impact statements commemorating the twentieth anniversary of the National Cancer Act of 1971—and now this historic document has been digitized and made searchable in the Cancer History Project.
Ruben A. Mesa was named president and executive director of the cancer service line of Atrium Health.
Yolanda Sanchez was named director and CEO of The University of New Mexico Comprehensive Cancer Center.
U.S. Rep. Debbie Wasserman Schultz (D-FL), Sen. Amy Klobuchar (D-MN), Sen. Ben Cardin (D-MD), Rep. Brian Fitzpatrick (R-PA), and Rep. Mark DeSaulnier (CA-11) introduced The Comprehensive Cancer Survivorship Act, a legislation that will address gaps in survivorship care and develop standards to improve the overall patient-centered quality of care and navigation needs of cancer survivors and their families.
The Max Foundation, a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally, will launch access to the Novartis therapy Scemblix (asciminib) in 36 low- and middle-income countries in 2023 for people living with chronic myeloid leukemia as part of the CancerPath to Care collaboration with Novartis.
FDA’s Oncology Center of Excellence published a Request for Applications for projects aimed at developing and implementing new approaches to support drug development for ultra-rare pediatric and adult cancers.
Fight Colorectal Cancer is committing $150,000 per year for a three-year research fellowship to study clinical data at Tempus, an artificial intelligence and precision medicine company.
